(All fields required)
Please enter a valid email.
Please enter your name.
Our research focuses on the biology of the eosinophil-lineage committed progenitor (EoP). We aim to identify novel therapeutic targets to regulate eosinophil production for the treatment of patients with inflammatory disorders by investigating transcriptional regulation of EoP generation and identifying and characterizing pathways important for EoP survival, proliferation and differentiation into mature eosinophils.
We have developed a number of innovative methods to study the regulation of eosinophil development including liquid culture systems in which we can follow differentiation of both murine and human eosinophil-lineage committed progenitors (EoPs) into mature effector eosinophils.
The pathways that we identify in our culture systems are tested in models of hypereosinophilia, infection and allergic inflammation to further characterize the clinical and therapeutic potential of candidate targets.
Eosinophil-associated disorders, including eosinophilic gastrointestinal disorders and asthma, are widely prevalent in developed and developing countries.
Current therapies can be effective, but resistance and toxic side effects often develop. New therapeutic agents are needed to treat patients with eosinophilic disorders.
Stem cell differentiation colony containing myeloid progenitors.
Fulkerson Lab Strategy Session
Jerilyn, Patty and Kaila (left to right) discussing data and progress and planning future experiments.
David is a postdoctoral clinical fellow in the Division of Allergy and Immunology. His research focuses on characterizing eosinophil progenitors mobilized from the bone marrow in patients with allergy and eosinophilic diseases.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2013 Cincinnati Children's Hospital Medical Center